← All trials
NCT01407822
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 5, 2011
- Primary completion
- Jun 1, 2017
- Completion date
- Mar 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Guangdong Association of Clinical TrialsLead sponsor
- Jilin Provincial Tumor HospitalCollaborator
- Peking UniversityCollaborator
- Shantou UniversityCollaborator
- Fudan UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sichuan UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Guangdong Academy of Medical SciencesOverall official - principal investigator
- Guangdong Academy of Medical SciencesStudy director
- Linyi Tumour HospitalCollaborator
- Fujian Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Tianjin Medical UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Guangdong Association of Clinical TrialsReponsible party - principal investigator
- Shantou UniversityStudy chair
- Dalian Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.